Key clinical point: The POP AGE trial implies clopidoprel is the P2Y12 inhibitor of choice in elderly patients with non-ST-elevation ACS.
Major finding: The rate of major and minor bleeding was 17.6% with clopidogrel, compared with 23.1% in the ticagrelor group, for a highly significant 26% reduction in relative risk.
Study details: POPular AGE, an 11-center Dutch RCT, included 1,003 patients age 70 or older with non-ST-elevation ACS.
Disclosures: The presenter reported having no financial conflicts regarding the study, funded by the Dutch government.
Gimbel ME. ESC 2019, Abstract 84.